Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Pharmaceuticals Inc.

Division of Johnson & Johnson
www.janssenpharmaceuticalsinc.com

Latest From Janssen Pharmaceuticals Inc.

Will Slew of Patent Bills Lower Drug Prices?

Legislation is targeting a wide range of patent practices, from product hopping to patent infringement settlements and inter partes review.

Legislation Pricing Debate

MSN Labs Gets FDA Nod For Zytiga Rival

India’s MSN Laboratories has won approval from the US health regulator to market its prostate cancer drug abiraterone acetate, a generic version of Janssen’s Zytiga. The clearance marks the latest in a string of FDA approvals for the fast-growing generic drugs company.

Strategy Generic Drugs

FDA Continuous Manufacturing Guidance Raises Concerns About Scope And Cost

Makers of brand pharmaceuticals focused on scope issues and the definition of terms in their comments on the US FDA's draft continuous manufacturing guidance, while makers of generic drugs raised concerns about cost and lack of benefit.

 

Manufacturing Quality

J&J Gambles Oklahoma Opioid Trial Is Better Than Settlement; State Seeks $870m Per Year

In opening statements, Oklahoma suggests award could be 'just shy of $13bn' if it takes 20 years to fix the problem.

Legal Issues Drug Safety
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register